Literature DB >> 21263033

Osteopontin-c splicing isoform contributes to ovarian cancer progression.

Tatiana M Tilli1, Vanessa Ferreira Franco, Bruno Kaufmann Robbs, João Luiz Mendes Wanderley, Fabrício Ribeiro de Azevedo da Silva, Kivvi Duarte de Mello, João P B Viola, Georg F Weber, Etel R Gimba.   

Abstract

Ovarian carcinoma is one of the most aggressive gynecological diseases and generally diagnosed at advanced stages. Osteopontin (OPN) is one of the proteins overexpressed in ovarian cancer and is involved in tumorigenesis and metastasis. Alternative splicing of OPN leads to 3 isoforms, OPNa, OPNb, and OPNc. However, the expression pattern and the roles of each of these isoforms have not been previously characterized in ovarian cancer. Herein, we have evaluated the expression profiling of OPN isoforms in ovarian tumor and nontumor samples and their putative roles in ovarian cancer biology using in vitro and in vivo functional assays. OPNa and OPNb were expressed both in tumor and nontumor ovarian samples, whereas OPNc was specifically expressed in ovarian tumor samples. The isoform OPNc significantly activated OvCar-3 cell proliferation, migration, invasion, anchorage-independent growth and tumor formation in vivo. Additionally, we have also shown that some of the OPNc-dependent protumorigenic roles are mediated by PI3K/Akt signaling pathway. OPNc stimulated immortalized ovarian epithelial IOSE cell proliferation, indicating a role for this isoform in ovarian cancer tumorigenesis. Functional assays using OPNc conditioned medium and an anti-OPNc antibody have shown that most cellular effects observed herein were promoted by the secreted OPNc. According to our data, OPNc-specific expression in ovarian tumor samples and its role on favoring different aspects of ovarian cancer progression suggest that secreted OPNc contributes to the physiopathology of ovarian cancer progression and tumorigenesis. Altogether, the data open possibilities of new therapeutic approaches for ovarian cancer that selectively down regulate OPNc, altering its properties favoring ovarian tumor progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21263033     DOI: 10.1158/1541-7786.MCR-10-0463

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  35 in total

Review 1.  Potential molecular targeting of splice variants for cancer treatment.

Authors:  Christopher A Blair; Xiaolin Zi
Journal:  Indian J Exp Biol       Date:  2011-11       Impact factor: 0.818

Review 2.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

3.  IL-7 splicing variant IL-7δ5 induces EMT and metastasis of human breast cancer cell lines MCF-7 and BT-20 through activation of PI3K/Akt pathway.

Authors:  Jie Yang; Zhi Zeng; Yuyu Peng; Jianhua Chen; Ling Pan; Deshun Pan
Journal:  Histochem Cell Biol       Date:  2014-04-26       Impact factor: 4.304

4.  Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN.

Authors:  Konrad Sarosiek; Elizabeth Jones; Galina Chipitsyna; Mazhar Al-Zoubi; Christopher Kang; Shivam Saxena; Ankit V Gandhi; Jocelyn Sendiky; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2015-01-13       Impact factor: 3.452

5.  Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1.

Authors:  Jintang Sun; Alei Feng; Songyu Chen; Yun Zhang; Qi Xie; Meixiang Yang; Qianqian Shao; Jia Liu; Qifeng Yang; Beihua Kong; Xun Qu
Journal:  Cell Mol Immunol       Date:  2013-02-18       Impact factor: 11.530

6.  Clinical value of TV-CDS combined with serum tumor markers in diagnosis of ovarian cancer.

Authors:  Chunying Yu; Ting Dou; Yun Liu; Ruirong Liu
Journal:  Oncol Lett       Date:  2020-06-05       Impact factor: 2.967

7.  Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma.

Authors:  Ali A Siddiqui; Elizabeth Jones; Darren Andrade; Apeksha Shah; Thomas E Kowalski; David E Loren; Galina Chipitsyna; Hwyda A Arafat
Journal:  J Gastroenterol Hepatol       Date:  2014-06       Impact factor: 4.029

8.  Intranasal administration of vitamin D attenuates blood-brain barrier disruption through endogenous upregulation of osteopontin and activation of CD44/P-gp glycosylation signaling after subarachnoid hemorrhage in rats.

Authors:  Budbazar Enkhjargal; Devin W McBride; Anatol Manaenko; Cesar Reis; Yasushi Sakai; Jiping Tang; John H Zhang
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

9.  Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus.

Authors:  Ornella J Rullo; Jennifer M P Woo; Miriam F Parsa; Alice D C Hoftman; Paul Maranian; David A Elashoff; Timothy B Niewold; Jennifer M Grossman; Bevra H Hahn; Maureen McMahon; Deborah K McCurdy; Betty P Tsao
Journal:  Arthritis Res Ther       Date:  2013-01-23       Impact factor: 5.156

10.  Correlation between ovarian neoplasm and serum levels of osteopontin: a meta-analysis.

Authors:  Yue-Dong Wang; He Chen; Hui-Qiag Liu; Min Hao
Journal:  Tumour Biol       Date:  2014-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.